Panacea Index Logo

Command Palette

Search for a command to run...

Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
September 1, 2018
Alberto Mazza et al. (9 authors)
Journal ArticleMulticenter StudyRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether Coenzyme Q10, combined with red yeast rice and added to diet and lifestyle management, was more effective than diet alone in improving blood pressure, lipid, and glucose profiles in patients with metabolic syndrome.

Results Summary

The study found that Coenzyme Q10 supplementation significantly improved systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, triglycerides, and glucose levels compared to diet alone, with no significant changes in HDL cholesterol. The treatment was well-tolerated and safe.

Population

104 subjects with metabolic syndrome (mean age 57.4 ± 8.8 years, 51% males) without a history of cardiovascular diseases.

Effective Dosage

Once-daily oral formulation (specific dosage not detailed).

Duration

2 months.

Interactions

None mentioned.

Extracted Claims (10)
InterventionDirectionEndpointPopulationDosageImpactClaim #
NCs containing red yeast rice and coenzyme Q10 added to diet
decrease
BP, TC, TG, LDLC and glucose levels
104 subjects with MetS without history of cardio-vascular diseases
-
A significant reduction
#1
NCs containing red yeast rice and coenzyme Q10 added to diet
decrease
systolic BP
52 subjects treated with NCs
-5.2 vs. -3.0 mmHg
a greater reduction
#2
NCs containing red yeast rice and coenzyme Q10 added to diet
decrease
diastolic BP
52 subjects treated with NCs
-4.9 vs. 2.9 mmHg
a greater reduction
#3
NCs containing red yeast rice and coenzyme Q10 added to diet
decrease
total cholesterol
52 subjects treated with NCs
-17.2%
a greater reduction
#4
NCs containing red yeast rice and coenzyme Q10 added to diet
decrease
LDLC
52 subjects treated with NCs
-21.8%
a greater reduction
#5
NCs containing red yeast rice and coenzyme Q10 added to diet
decrease
TG
52 subjects treated with NCs
-16.0%
a greater reduction
#6
NCs containing red yeast rice and coenzyme Q10 added to diet
decrease
serum glucose
52 subjects treated with NCs
-3.4%
a greater reduction
#7
NCs containing red yeast rice and coenzyme Q10 added to diet
no change
HDLC
52 subjects treated with NCs
-
remained unchanged
#8
diet program
decrease
BP, TC, TG, LDLC and glucose levels
52 patients following a diet program
-
A significant reduction
#9
NC supplementation
increase
clinic BP, lipid and glucose profile
patients with MetS
-
effective in improving
#10
Abstract

INTRODUCTION: Metabolic syndrome (MetS) is a world-wide epidemic disease with an increased risk of morbidity and mortality. Treatment strategies of MetS include pharmacologic and non-pharmacologic interventions and in this respect a relevant role has been shown for nutraceutical compounds (NCs). The aim of this study was to investigate the efficacy and safety of NCs incorporated with diet and lifestyle management versus diet alone, in lowering blood pressure (BP) values and improving lipid and glucose profile, in a group of hypertensives and hyper-cholesterolemic patients with MetS. METHODS: 104 subjects with MetS (mean age 57.4 ± 8.8 years, 51% males) without history of cardio-vascular (CV) diseases were enrolled in the study. 52 subjects were treated with a once-daily oral formulation of a NCs containing red yeast rice and coenzyme Q10 added to their diet for 2 months and were compared with the 52 patients following a diet program. Differences in BP, serum total cholesterol (TC), low- and high-density-lipoprotein cholesterol (LDLC and HDLC), triglycerides (TG) and glucose values were compared by analysis of variance. RESULTS: A significant reduction of BP, TC, TG, LDLC and glucose levels was observed in both treatment groups. However, a greater reduction of systolic BP (-5.2 vs. -3.0 mmHg), diastolic BP (-4.9 vs. 2.9 mmHg), total cholesterol (-17.2%), LDLC (-21.8%), TG (-16.0%) and serum glucose (-3.4%) was observed in the treatment group relative to the control (p < 0.001 for all); HDLC remained unchanged (p = N.S.). Gender difference was not found in either group (p = N.S.). CONCLUSIONS: In patients with MetS, NC supplementation was safe, well tolerated and effective in improving clinic BP, lipid and glucose profile.

Medical Subject Headings (MeSH)
AgedAnticholesteremic AgentsBlood GlucoseCholesterol, HDLCholesterol, LDLDiet, MediterraneanDietary SupplementsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHypertensionLovastatinMaleMetabolic SyndromeMiddle AgedTreatment OutcomeTriglyceridesUbiquinone
Study Links
Quality Scores
Safety90
Efficacy85/10
Quality80/10
Citation Metrics
Total Citations18
Citations/Year2.6
Relative Citation Ratio1.00
NIH Percentile50.2%
Research Impact Scores
APT Score0.25
Weight Score2.11
Normalized Score0.86
Related Supplements